Clinical Trial Assistant

Executive Assistant II

Scientist I

Vice President, Legal

Vice President,Intellectual Property

Clinical Trials Manager

Associate Director,  Statistical Programming

Quality Assurance Specialist 

Vice President, Business Development and Corporate Strategy

Medical Director

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

8Biomed

A-Alpha Bio

A2 Biotherapeutics

AavantiBio

AB Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

ACELYRIN

Acepodia

Achieve Life Sciences

Acrivon Therapeutics

Acutis Diagnostics

Adagio Therapeutics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

adMare BioInnovations

Admera Health

Adverum Biotechnologies

adyn

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agena Bioscience

Akero Therapeutics

Akouos

Alamar Biosciences

Alector

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

AllStripes

Alltrna

Alpine Immune Sciences

Altis Biosystems

Alto Neuroscience

AltPep

Alumis

Alveo Technologies

ALX Oncology

Alzheon

Ambagon Therapeutics

Amberstone Biosciences

Ambys Medicines

Amylyx

AN2 Therapeutics

Andes

Angiocrine Bioscience

AnHeart Therapeutics

Annexon Biosciences

Ansa Biotechnologies

Antheia

Apollomics

Appia Bio

Applied Molecular Transport

Apriori Bio (Flagship)

Aptevo Therapeutics

Apton Biosystems

Aptose Biosciences

Aquinnah Pharmaceuticals

Arbor Biotechnologies

Arcadia Science

Arcellx

Arcturus Therapeutics

Arcutis Biotherapeutics

Arima Genomics

Ark Biotech

Arkuda Therapeutics

Armata Pharmaceuticals

Aro Biotherapeutics

Arpeggio Biosciences

Arrakis Therapeutics

Arranta Bio

ArsenalBio

Artisan Bio

Artiva Biotherapeutics

Aruvant

Ascidian Therapeutics

Ascribe Bioscience

Lyell Immunopharma is using the latest insights in immunology to reprogram T cells to cure cancer. CAR T cells have had most success so far in treating patients with B cell lymphomas. However, around 90% of all cancers are solid tumors where only limited success with cell therapies has been seen. Lyell is using their proprietary epigenetic and genetic reprogramming technologies to develop cell therapies to address these tumors for reliable and curative responses. Lyell’s approach involves identifying the “active ingredient” of adoptive cell therapies to either overcome loss of T cell function or to create T cell populations with durable stemness to infiltrate tumors. Lyell’s lead product, LYL797 is in Phase 1 clinical trials for non-small cell lung cancer, with other products in the pipeline.

<p>Lyell Immunopharma is using the latest insights in immunology to reprogram T cells to cure cancer. CAR T cells have had most success so far in treating patients with B cell lymphomas. However, around 90% of all cancers are solid tumors where only limited success with cell therapies has been seen. Lyell is using their proprietary epigenetic and genetic reprogramming technologies to develop cell therapies to address these tumors for reliable and curative responses. Lyell’s approach involves identifying the “active ingredient” of adoptive cell therapies to either overcome loss of T cell function or to create T cell populations with durable stemness to infiltrate tumors. Lyell’s lead product, LYL797 is in Phase 1 clinical trials for non-small cell lung cancer, with other products in the pipeline.</p>


Lyell Immunopharma

Find a biotech startup job.